Toggle light / dark theme

Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL).

Updated findings from the UNITY-CLL clinical trial continued to show a possible increased risk of death in patients receiving Ukoniq. As a result, we determined the risks of treatment with Ukoniq outweigh its benefits. Based upon this determination, the drug’s manufacturer, TG Therapeutics, announced it was voluntarily withdrawing Ukoniq from the market for the approved uses in MZL and FL.

Health care professionals should stop prescribing Ukoniq and switch patients to alternative treatments. Inform patients currently taking Ukoniq of the increased risk of death seen in the clinical trial and advise them to stop taking the medicine. In limited circumstances in which a patient may be receiving benefit from Ukoniq, TG Therapeutics plans to make it available under expanded access.

Using the patient’s own cellsAn American biotech company has just announced that they have successfully transplanted a 3D printed human ear into a patient, initially reported by The New York Times. The company, Queens-based 3DBio Therapeutics, printed the ear using the patient’s own cells.


In what has been described as a world first, a U.S. company has created and transplanted a 3D-printed ear made of the patient’s own cells.

DeLorean released images and information on its upcoming 2024 electric car.

DeLorean is unapologetically human. A New Energy mobility brand.

We have a clear vision of our future, knowing it does not represent today. The DMC-12 was never meant to be a static interpretation of the brand, the brand would constantly evolve. Our icons are reimagined. DMC is and always was in constant evolution. An Icon is validated over time but to constantly reimagine mobility allows new icons to come into existence.


DeLorean is a legacy mobility company focused on redefining human connections through creative technologies.

Electric organs help electric fish, such as the electric eel, do all sorts of amazing things: They send and receive signals that are akin to bird songs, helping them to recognize other electric fish by species, sex and even individual. A new study in Science Advances explains how small genetic changes enabled electric fish to evolve electric organs. The finding might also help scientists pinpoint the genetic mutations behind some human diseases.

Evolution took advantage of a quirk of genetics to develop electric organs. All fish have duplicate versions of the same gene that produces tiny muscle motors, called . To evolve electric organs, electric fish turned off one duplicate of the channel gene in muscles and turned it on in other cells. The tiny motors that typically make muscles contract were repurposed to generate electric signals, and voila! A new organ with some astonishing capabilities was born.

“This is exciting because we can see how a small change in the gene can completely change where it’s expressed,” said Harold Zakon, professor of neuroscience and integrative biology at The University of Texas at Austin and corresponding author of the study.

Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed a stretchable and waterproof €˜fabric €™ that turns energy generated from body movements into electrical energy.

A crucial component in the fabric is a polymer that, when pressed or squeezed, converts mechanical stress into electrical energy. It is also made with stretchable spandex as a base layer and integrated with a rubber-like material to keep it strong, flexible, and waterproof.

In a proof-of-concept experiment reported in the scientific journal Advanced Materials (“Stretchable, Breathable, and Stable Lead-Free Perovskite/Polymer Nanofiber Composite for Hybrid Triboelectric and Piezoelectric Energy Harvesting”), the NTU Singapore team showed that tapping on a 3cm by 4cm piece of the new fabric generated enough electrical energy to light up 100 LEDs.

SpaceX could begin launching the fourth of five orbital ‘shells’ of its first Starlink constellation as early as July, according to a report from a reliable source of SpaceX information.

The initial report tweeted on May 20th by reporter Alejandro Alcantarilla claimed that SpaceX was preparing to start launching “Group 3” of its first 4408-satellite Starlink constellation as early as July 2022. Less than a week later, those claims were confirmed when SpaceX applied for communications permits known as “special temporary authority” licenses or STAs for a launch known as “Starlink Group 3−1” no earlier than late June.

“Group 3” refers to one of five orbital “shells” that make up SpaceX’s 4408-satellite first-generation Starlink constellation. Each shell can be thought of more or less as, well, a shell – a thin layer of satellites more or less evenly distributed around the entire sphere of the Earth. Shells mainly differ by two measures: orbital inclination (the angle between a given orbit and the Earth’s equator) and orbital altitude (the distance from the orbit to the ground).